拓扑异构酶IIα和β在耐药性中的作用。 - Suppr

Suppr

超能文献

The role of topoisomerase II alpha and beta in drug resistance.

作者信息

Hochhauser D, Harris A L

机构信息

Imperial Cancer Research Fund, University of Oxford, John Radcliffe Hospital, U.K.

出版信息

Cancer Treat Rev. 1993 Apr;19(2):181-94. doi: 10.1016/0305-7372(93)90034-o.

DOI:10.1016/0305-7372(93)90034-o

PMID:8386983

Abstract

摘要

相似文献

The role of topoisomerase II alpha and beta in drug resistance.拓扑异构酶IIα和β在耐药性中的作用。

Cancer Treat Rev. 1993 Apr;19(2):181-94. doi: 10.1016/0305-7372(93)90034-o.

[Multidrug resistance of neoplastic cells--facts and hypotheses].[肿瘤细胞的多药耐药性——事实与假说]

Postepy Biochem. 1989;35(4):513-41.

The role of DNA topoisomerases II in drug resistance.DNA拓扑异构酶II在耐药性中的作用。

Br J Haematol. 1993 Oct;85(2):241-5. doi: 10.1111/j.1365-2141.1993.tb03162.x.

Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.DNA拓扑异构酶II的表达降低赋予了从一名患者的难治性肿瘤建立的小细胞肺癌细胞系以及通过体外筛选得到的细胞系对依托泊苷（VP - 16）的抗性。

Oncol Res. 1996;8(6):229-38.

Drug resistance associated with altered DNA topoisomerase II.与DNA拓扑异构酶II改变相关的耐药性。

Adv Enzyme Regul. 1993;33:113-27. doi: 10.1016/0065-2571(93)90012-3.

Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II.耐药性P388小鼠白血病、中国仓鼠卵巢细胞和人宫颈癌细胞系对抗肿瘤药物的多因素耐药性，重点关注DNA拓扑异构酶II的作用。

Biochem Cell Biol. 1992 May;70(5):354-64. doi: 10.1139/o92-055.

Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.拓扑异构酶I和II参与镉诱导中国仓鼠卵巢细胞金属硫蛋白表达的证据。

Anticancer Drug Des. 1989 Aug;4(2):107-24.

Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.HL-60白血病细胞中的米托蒽醌耐药性：核拓扑异构酶II催化活性降低以及药物诱导的DNA切割减少，同时拓扑异构酶IIβ同工型表达降低。

Biochemistry. 1991 Oct 15;30(41):9953-61. doi: 10.1021/bi00105a020.

DNA-topoisomerase I and II: biologic features and their role in drug resistance.DNA拓扑异构酶I和II：生物学特性及其在耐药性中的作用。

Haematologica. 1993 Jul-Aug;78(4):201-7.

[Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].[DNA拓扑异构酶抑制剂耐药机制研究的最新进展]

Gan To Kagaku Ryoho. 1994 Jun;21(7):952-61.

引用本文的文献

Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R).亚磺肌苷通过协同作用并逆转人非小细胞肺癌细胞系（NCI-H460/R）中的多药耐药性来增强阿霉素的疗效。

Invest New Drugs. 2009 Apr;27(2):99-110. doi: 10.1007/s10637-008-9140-5. Epub 2008 May 21.

Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia.在一种高度耐药的P388白血病中，Bcl-X蛋白长形式的自发过表达。

Br J Cancer. 1997;75(2):268-74. doi: 10.1038/bjc.1997.44.

Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.DNA拓扑异构酶II抑制剂在耐药肿瘤细胞中的新作用。

Cancer Chemother Pharmacol. 1994;34 Suppl:S14-8. doi: 10.1007/BF00684858.

Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.体外暴露于特定抗肿瘤药物或辐射所导致的不同交叉耐药模式。

Cytotechnology. 1993;12(1-3):265-88. doi: 10.1007/BF00744668.

"Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).在对多柔比星产生抗性的人卵巢癌细胞系A2780（A2780 DX3）中筛选出的“非典型”多药抗性。

J Cancer Res Clin Oncol. 1995;121(3):155-63. doi: 10.1007/BF01198097.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验